Deals In Depth: July 2019
Gilead continued its R&D relationship with Galapagos in a new, nearly $10bn alliance. Exact Sciences and Genomic Health merged in a $2.8bn agreement creating a leading global molecular diagnostics company. Pharma financing was down while device funding increased thanks to a strong showing in the debt category, including ResMed's $498m offering.
You may also be interested in...
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.